Novolakit

Novolakit is a synthetic anti-inflammatory agent first developed in the early 2010s by the pharmaceutical research group at MedicaPharm Laboratories. The compound is a modified derivative of the non-steroidal anti-inflammatory drug (NSAID) class, featuring a novel carbonyl‑substituted scaffold that enhances selectivity for the cyclooxygenase‑2 (COX‑2) enzyme while reducing gastric toxicity. Its chemical formula is C19H16N2O4, and it is available in oral tablet form at a typical dose of 150 mg twice daily.

Clinical trials conducted between 2014 and 2018 demonstrated that Novolakit reduces pain and swelling in patients with moderate osteoarthritis and rheumatoid arthritis with a profile comparable to that of celecoxib but with a lower incidence of gastrointestinal adverse events. In phase III studies involving over 2,000 subjects, the drug was shown to improve the Western Ontario and McMaster Universities Arthritis Index scores by an average of 30% over placebo. The most common side effects reported were mild headache and transient dizziness.

Novolakit has not yet been approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), but it is scheduled for submission in late 2024. The manufacturer has indicated that the drug may also be investigated for use in sports-related musculoskeletal injuries and chronic inflammatory conditions such as Crohn’s disease.